David Vail

7PUBLICATIONS
56CO-AUTHORS
Haematological tumoursCancer diagnosisMolecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 16, 2026
Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumours.

|Aug 19, 2025
In vitro detection of canine anti-human antibodies following intratumoral injection of the hu14.18-IL2 immunocytokine in spontaneous canine melanoma.

Andrew T Kosharek, Cindy L Zuleger, William S Glass

|Jun 18, 2024
Population Pharmacokinetics, Pharmacodynamics and Safety Properties of Trametinib in Dogs With Cancer: A Phase I Dose Escalating Clinical Trial.

Marilia Takada, Keita Kitagawa, Yongzhen Zhang

|Jul 25, 2022
Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing Dogs.

Amy K LeBlanc, Christina N Mazcko, Timothy M Fan

|Aug 12, 2021
Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.

Kara Magee, Ian R Marsh, Michelle M Turek

|Jul 15, 2021
Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.

Ravi B Patel, Reinier Hernandez, Peter Carlson

Pageof 2

Frequent Collaborators

2 joint publications

Brian K Flesner

2 joint publications

Jeffrey N Bryan

1 joint publications

Erika P Berger

1 joint publications

William C Kisseberth